Sareum (LON:SAR) Share Price Passes Below 50-Day Moving Average – What’s Next?

Shares of Sareum Holdings plc (LON:SAR) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 15.76 ($0.21) and traded as low as GBX 15 ($0.20). Sareum shares last traded at GBX 15.30 ($0.21), with a volume of 361,686 shares.

Sareum Stock Up 1.2%

The stock has a fifty day simple moving average of GBX 15.76 and a 200 day simple moving average of GBX 20.30. The firm has a market capitalization of £19.59 million, a P/E ratio of -3.71 and a beta of -1.08.

Sareum (LON:SAR) last released its earnings results on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) earnings per share (EPS) for the quarter. Research analysts anticipate that Sareum Holdings plc will post -3.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Sareum

In other news, insider Stephen Parker purchased 84,033 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of GBX 12 ($0.16) per share, with a total value of £10,083.96 ($13,535.52). Insiders own 5.02% of the company’s stock.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.